Uy Ear
Stock Analyst at Mizuho
(1.05)
# 1938
Out of 5,331 analysts
68
Total ratings
37.04%
Success rate
9.57%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
TECX Tectonic Therapeutic | Initiates Coverage On: Outperform | 51 | 21.68 | 135.24% | 1 | Apr 21, 2025 | |
ARQT Arcutis Biotherapeut... | Maintains: Outperform | 20 21 | 15.23 | 37.89% | 14 | Feb 26, 2025 | |
QURE uniQure | Maintains: Neutral | 7 20 | 14.8 | 35.14% | 4 | Dec 19, 2024 | |
RLMD Relmada Therapeutics | Downgrades: Neutral | 23 1 | 0.36 | 177.78% | 1 | Dec 5, 2024 | |
ALKS Alkermes | Maintains: Outperform | 35 40 | 31.82 | 25.71% | 5 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 18 16 | 7.27 | 120.08% | 2 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | 12.8 | 212.5% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 145 179 | 63.49 | 181.93% | 5 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 25 21 | 14.88 | 41.13% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 20 23 | 12.09 | 90.24% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 116 140 | 109.71 | 27.61% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 24 | n/a | n/a | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 16 | n/a | n/a | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | n/a | n/a | 2 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 40 | 156.03 | -74.36% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 10 | 1.34 | 646.27% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | 0.77 | 289.61% | 2 | Mar 1, 2023 |